Study identifier:D4300C00011
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An Open-label, Single-Centre Study to Assess the Pharmacokinetics of R406 in Healthy Volunteers when Fostamatinib Disodium 150 mg is Administered Alone and in Combination with Verapamil
Drug drug interactions, Healthy Volunteers
Phase 1
Yes
FOSTAMATIN, Verapamil
All
15
Interventional
18 Years - 55 Years
Allocation: Non-randomized 
Endpoint Classification: Safety Study 
Intervention Model: Crossover Assignment 
Masking: Open Label 
Primary Purpose: Basic Science 
Verified 01 Apr 2014 by AstraZeneca
AstraZeneca
-
No locations available
| Arms | Assigned Interventions | 
|---|---|
| Experimental: Period 1 | Drug: FOSTAMATIN  Oral tablets - single dose | 
| Experimental: Period 2 | Drug: FOSTAMATIN  Oral tablets - single dose Drug: Verapamil  Oral tablets – administered 3 times daily over 4 days |